Neprilysin
(Homo sapiens (Human)) | BDBM300272
(US9593110, 62)Show SMILES OC(=O)[C@@H](C[C@@H](Cc1ccc(cc1)-c1cc(Cl)ccc1F)NC(=O)c1cnn[nH]1)Cn1ccnc1 Show InChI InChI=1S/C24H22ClFN6O3/c25-18-5-6-21(26)20(11-18)16-3-1-15(2-4-16)9-19(29-23(33)22-12-28-31-30-22)10-17(24(34)35)13-32-8-7-27-14-32/h1-8,11-12,14,17,19H,9-10,13H2,(H,29,33)(H,34,35)(H,28,30,31)/t17-,19+/m0/s1 | PDB
KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| <1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Theravence Biopharma R&D IP, LLC
US Patent
| Assay Description Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp... |
US Patent US9593110 (2017)
BindingDB Entry DOI: 10.7270/Q2MC9224 |